Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DPIs CONSIDERED MEDICALLY ACCEPTABLE ALTERNATIVE TO CFC PRODUCTS, FDA ADVISORY CMTE. SAYS; POTENCIES OF CFC-FREE AND CFC PRODUCTS SHOULD BE COMPARED

Executive Summary

Dry powder inhalers are a technically and medically feasible alternative to CFC-containing metered dose inhalers, FDA's Pulmonary-Allergy Drugs Advisory Committee concluded at its April 11 meeting. "What we are hearing...is that people feel that there is a role for DPIs, and with most patients they could be a substitute," summarized Committee Chairperson Shirley Murphy, MD, University of New Mexico.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel